AR046094A1 - COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB - Google Patents

COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB

Info

Publication number
AR046094A1
AR046094A1 ARP040103643A ARP040103643A AR046094A1 AR 046094 A1 AR046094 A1 AR 046094A1 AR P040103643 A ARP040103643 A AR P040103643A AR P040103643 A ARP040103643 A AR P040103643A AR 046094 A1 AR046094 A1 AR 046094A1
Authority
AR
Argentina
Prior art keywords
human
chain variable
variable region
antibody
region comprises
Prior art date
Application number
ARP040103643A
Other languages
Spanish (es)
Inventor
Maria Jure-Kungel
Laura J Hefta
Marc Santoro
Subinay Ganguly
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37426115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR046094A1 publication Critical patent/AR046094A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos completamente humanos y porciones de enlace de antígenos de los mismos que se enlazan al 4-1BB humano y que permiten el enlace del 4-1BB humano al ligando 4-1BB humano, así como polinucleótidos que codifican dichos polipéptidos. En un aspecto el anticuerpo es el anticuerpo IgG4. También se suministra un método para el tratamiento del cáncer en un sujeto que comprende administrar una cantidad terapéuticamente efectiva del anticuerpo al sujeto. Reivindicación 1: Un anticuerpo monoclonal o porción de enlace de antígeno del mismo que se enlaza específicamente a 4-1BB, caracterizado porque comprende una región variable de cadena ligera una región variable de cadena pesada, en donde: la región variable de cadena ligera comprende un CDR1, un CDR2 y un CDR3 como se detalla en la figura (4); y la región variable de cadena pesada comprende un CDR1, un CDR2, y un CDR3 como se detalla en la figura (3).Fully human antibodies and antigen binding portions thereof that bind to human 4-1BB and which allow the binding of human 4-1BB to human 4-1BB ligand, as well as polynucleotides encoding said polypeptides. In one aspect the antibody is the IgG4 antibody. A method is also provided for the treatment of cancer in a subject comprising administering a therapeutically effective amount of the antibody to the subject. Claim 1: A monoclonal antibody or antigen binding portion thereof that specifically binds to 4-1BB, characterized in that a light chain variable region comprises a heavy chain variable region, wherein: the light chain variable region comprises a CDR1, a CDR2 and a CDR3 as detailed in Figure (4); and the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 as detailed in Figure (3).

ARP040103643A 2003-10-10 2004-10-07 COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB AR046094A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51019303P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
AR046094A1 true AR046094A1 (en) 2005-11-23

Family

ID=37426115

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103643A AR046094A1 (en) 2003-10-10 2004-10-07 COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB

Country Status (5)

Country Link
CN (1) CN1867585B (en)
AR (1) AR046094A1 (en)
PE (1) PE20050962A1 (en)
TW (1) TWI332844B (en)
ZA (1) ZA200602834B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357961A (en) * 2018-04-10 2019-10-22 无锡智康弘义生物科技有限公司 Anti-human 4-1BB monoclonal antibody and its preparation method and application
CN112010974A (en) * 2019-05-30 2020-12-01 山东博安生物技术有限公司 Antibody specifically binding to human 4-1BB and application thereof
US11555077B2 (en) 2017-11-09 2023-01-17 Shanghai Hyamab Biotech Co., Ltd. 4-1BB antibody and preparation method and use thereof
US12054554B2 (en) 2018-04-10 2024-08-06 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2614082T3 (en) * 2010-09-09 2018-11-26 Pfizer 4-1BB BINDING MOLECULES
KR101503341B1 (en) 2014-03-12 2015-03-18 국립암센터 Methods for isolation and proliferation of autologous cancer antigen-specific CD8+ T cells
JP2018520650A (en) * 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー Novel polypeptide
US10875926B2 (en) 2015-09-22 2020-12-29 Dingfu Biotarget Co., Ltd. Fully human antibody against human CD 137
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
SG10201914064QA (en) 2017-01-06 2020-03-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
JP7323513B2 (en) * 2017-06-25 2023-08-08 システィミューン， インク． ANTI-4-1BB ANTIBODY AND METHOD OF PRODUCTION AND USAGE THEREOF
MX2020000342A (en) * 2017-07-11 2020-08-17 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof.
CN111511762A (en) * 2017-08-21 2020-08-07 天演药业公司 anti-CD137 molecules and uses thereof
WO2019072274A1 (en) * 2017-10-12 2019-04-18 瑞阳(苏州)生物科技有限公司 Agonistic 4-1bb monoclonal antibody
CN109651507B (en) 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 Excited 4-1BB monoclonal antibody
RU2020127196A (en) * 2018-01-22 2022-02-24 Цзянсу Хэнжуй Медицин Ко., Лтд. ANTIBODY AGAINST 4-1BB, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL APPLICATIONS
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
CN112867733B (en) * 2018-10-19 2023-01-06 苏州丁孚靶点生物技术有限公司 anti-CD 137 antibodies and uses thereof
CN111320691B (en) * 2018-12-17 2022-04-05 程联胜 Anti-human 4-1BB monoclonal antibody and application thereof
CN113842456B (en) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 Anti-human 4-1BB monoclonal antibody preparation and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029348A1 (en) * 1995-03-23 1996-09-26 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
NZ334691A (en) * 1996-10-11 2000-12-22 Bristol Myers Squibb Co Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11555077B2 (en) 2017-11-09 2023-01-17 Shanghai Hyamab Biotech Co., Ltd. 4-1BB antibody and preparation method and use thereof
CN110357961A (en) * 2018-04-10 2019-10-22 无锡智康弘义生物科技有限公司 Anti-human 4-1BB monoclonal antibody and its preparation method and application
CN110357961B (en) * 2018-04-10 2022-08-23 无锡智康弘义生物科技有限公司 Anti-human 4-1BB monoclonal antibody, preparation method and application thereof
US12054554B2 (en) 2018-04-10 2024-08-06 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof
CN112010974A (en) * 2019-05-30 2020-12-01 山东博安生物技术有限公司 Antibody specifically binding to human 4-1BB and application thereof

Also Published As

Publication number Publication date
ZA200602834B (en) 2007-07-25
PE20050962A1 (en) 2005-11-17
CN1867585A (en) 2006-11-22
TW200517124A (en) 2005-06-01
CN1867585B (en) 2011-02-09
TWI332844B (en) 2010-11-11

Similar Documents

Publication Publication Date Title
AR046094A1 (en) COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
ES2527961T3 (en) Human monoclonal antibodies to CD70
RS20060234A (en) Fully human antibodies against human 4-1bb (cd137)
CL2008002923A1 (en) Human monoclonal antibody isolated because it binds to human mesothelin; composition comprising said antibody; conjugate between antibody and therapeutic agent; nucleic acid molecule that encodes the antibody; use to prepare a drug to treat cancer.
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
GEP20074222B (en) Antibodies to cd40
ES2523194T3 (en) Specific human monoclonal antibody for each tumor
AR050642A1 (en) ANTI-5T4 HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5T4 ANTIBODY / CALICHEAMICINA
ES2572231T3 (en) Human anti-IL-21 monoclonal antibodies
RU2011116112A (en) BSPECIFIC ANTI-EGFR / ANTI-IGF-1R ANTIBODIES
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ES2572177T3 (en) Human anti-B7RP1 neutralizing antibodies
EA202092460A1 (en) ANTIBODIES TO OX40 AND METHODS OF APPLICATION
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
EA201490957A1 (en) TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY
PE20120079A1 (en) IMPROVED ANTIBODY MOLECULES
NZ575245A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
UA89350C2 (en) Humanized antibody that specifically binds human cd20
PE20120014A1 (en) HUMAN ANTIBODIES OF HIGH AFFINITY AGAINST PCSK9
NO20026063D0 (en) Antibodies to human MCP-1
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2011051327A3 (en) Small antibody-like single chain proteins
PE20061166A1 (en) ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-17
PE20080214A1 (en) ANTIBODY MOLECULES THAT JOIN HUMAN IL-17
DK1684869T3 (en) Method of Therapy for B-Cell-Related Cancer Diseases

Legal Events

Date Code Title Description
FG Grant; registration